

2018-2023 Global Performance Enhancing Drugs Consumption Market Report

<https://marketpublishers.com/r/2827CF1EC84EN.html>

Date: August 2018

Pages: 133

Price: US\$ 4,660.00 (Single User License)

ID: 2827CF1EC84EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Performance Enhancing Drugs market for 2018-2023.

Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.

A well-known example of PED involves doping in sport, where banned physical performance-enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance. Over the next five years, LPI(LP Information) projects that Performance Enhancing Drugs will register a xx% CAGR in terms of revenue, reach US\$ xx million by 2023, from US\$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Performance Enhancing Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

Ergogenic Aids

Nootropic

Segmentation by application:

Athletes

Body Builders

Students

Militaries

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Spain

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

Taj Pharmaceuticals

Balkan Pharmaceuticals

Bayer

AstraZeneca

Novo Nordisk

BrainAlert

Douglas Laboratories

Onnit Labs

Eli Lilly And Company

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Performance Enhancing Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.

To understand the structure of Performance Enhancing Drugs market by identifying its various subsegments.

Focuses on the key global Performance Enhancing Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Performance Enhancing Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Performance Enhancing Drugs submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Performance Enhancing Drugs Consumption 2013-2023
 - 2.1.2 Performance Enhancing Drugs Consumption CAGR by Region
- 2.2 Performance Enhancing Drugs Segment by Type
 - 2.2.1 Ergogenic Aids
 - 2.2.2 Nootropic
- 2.3 Performance Enhancing Drugs Consumption by Type
 - 2.3.1 Global Performance Enhancing Drugs Consumption Market Share by Type (2013-2018)
 - 2.3.2 Global Performance Enhancing Drugs Revenue and Market Share by Type (2013-2018)
 - 2.3.3 Global Performance Enhancing Drugs Sale Price by Type (2013-2018)
- 2.4 Performance Enhancing Drugs Segment by Application
 - 2.4.1 Athletes
 - 2.4.2 Body Builders
 - 2.4.3 Students
 - 2.4.4 Militaries
- 2.5 Performance Enhancing Drugs Consumption by Application
 - 2.5.1 Global Performance Enhancing Drugs Consumption Market Share by Application (2013-2018)
 - 2.5.2 Global Performance Enhancing Drugs Value and Market Share by Application (2013-2018)
 - 2.5.3 Global Performance Enhancing Drugs Sale Price by Application (2013-2018)

3 GLOBAL PERFORMANCE ENHANCING DRUGS BY PLAYERS

- 3.1 Global Performance Enhancing Drugs Sales Market Share by Players
 - 3.1.1 Global Performance Enhancing Drugs Sales by Players (2016-2018)
 - 3.1.2 Global Performance Enhancing Drugs Sales Market Share by Players (2016-2018)
- 3.2 Global Performance Enhancing Drugs Revenue Market Share by Players
 - 3.2.1 Global Performance Enhancing Drugs Revenue by Players (2016-2018)
 - 3.2.2 Global Performance Enhancing Drugs Revenue Market Share by Players (2016-2018)
- 3.3 Global Performance Enhancing Drugs Sale Price by Players
- 3.4 Global Performance Enhancing Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
 - 3.4.1 Global Performance Enhancing Drugs Manufacturing Base Distribution and Sales Area by Players
 - 3.4.2 Players Performance Enhancing Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 PERFORMANCE ENHANCING DRUGS BY REGIONS

- 4.1 Performance Enhancing Drugs by Regions
 - 4.1.1 Global Performance Enhancing Drugs Consumption by Regions
 - 4.1.2 Global Performance Enhancing Drugs Value by Regions
- 4.2 Americas Performance Enhancing Drugs Consumption Growth
- 4.3 APAC Performance Enhancing Drugs Consumption Growth
- 4.4 Europe Performance Enhancing Drugs Consumption Growth
- 4.5 Middle East & Africa Performance Enhancing Drugs Consumption Growth

5 AMERICAS

- 5.1 Americas Performance Enhancing Drugs Consumption by Countries
 - 5.1.1 Americas Performance Enhancing Drugs Consumption by Countries (2013-2018)
 - 5.1.2 Americas Performance Enhancing Drugs Value by Countries (2013-2018)
- 5.2 Americas Performance Enhancing Drugs Consumption by Type
- 5.3 Americas Performance Enhancing Drugs Consumption by Application
- 5.4 United States
- 5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Performance Enhancing Drugs Consumption by Countries

6.1.1 APAC Performance Enhancing Drugs Consumption by Countries (2013-2018)

6.1.2 APAC Performance Enhancing Drugs Value by Countries (2013-2018)

6.2 APAC Performance Enhancing Drugs Consumption by Type

6.3 APAC Performance Enhancing Drugs Consumption by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Performance Enhancing Drugs by Countries

7.1.1 Europe Performance Enhancing Drugs Consumption by Countries (2013-2018)

7.1.2 Europe Performance Enhancing Drugs Value by Countries (2013-2018)

7.2 Europe Performance Enhancing Drugs Consumption by Type

7.3 Europe Performance Enhancing Drugs Consumption by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Spain

7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Performance Enhancing Drugs by Countries

8.1.1 Middle East & Africa Performance Enhancing Drugs Consumption by Countries (2013-2018)

8.1.2 Middle East & Africa Performance Enhancing Drugs Value by Countries

(2013-2018)

8.2 Middle East & Africa Performance Enhancing Drugs Consumption by Type

8.3 Middle East & Africa Performance Enhancing Drugs Consumption by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.2 Performance Enhancing Drugs Distributors

10.3 Performance Enhancing Drugs Customer

11 GLOBAL PERFORMANCE ENHANCING DRUGS MARKET FORECAST

11.1 Global Performance Enhancing Drugs Consumption Forecast (2018-2023)

11.2 Global Performance Enhancing Drugs Forecast by Regions

11.2.1 Global Performance Enhancing Drugs Forecast by Regions (2018-2023)

11.2.2 Global Performance Enhancing Drugs Value Forecast by Regions (2018-2023)

11.2.3 Americas Consumption Forecast

11.2.4 APAC Consumption Forecast

11.2.5 Europe Consumption Forecast

11.2.6 Middle East & Africa Consumption Forecast

11.3 Americas Forecast by Countries

11.3.1 United States Market Forecast

11.3.2 Canada Market Forecast

11.3.3 Mexico Market Forecast

- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
 - 11.4.1 China Market Forecast
 - 11.4.2 Japan Market Forecast
 - 11.4.3 Korea Market Forecast
 - 11.4.4 Southeast Asia Market Forecast
 - 11.4.5 India Market Forecast
 - 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
 - 11.5.1 Germany Market Forecast
 - 11.5.2 France Market Forecast
 - 11.5.3 UK Market Forecast
 - 11.5.4 Italy Market Forecast
 - 11.5.5 Russia Market Forecast
 - 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
 - 11.6.1 Egypt Market Forecast
 - 11.6.2 South Africa Market Forecast
 - 11.6.3 Israel Market Forecast
 - 11.6.4 Turkey Market Forecast
 - 11.6.5 GCC Countries Market Forecast
- 11.7 Global Performance Enhancing Drugs Forecast by Type
- 11.8 Global Performance Enhancing Drugs Forecast by Application

12 KEY PLAYERS ANALYSIS

- 12.1 Taj Pharmaceuticals
 - 12.1.1 Company Details
 - 12.1.2 Performance Enhancing Drugs Product Offered
 - 12.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.1.4 Main Business Overview
 - 12.1.5 Taj Pharmaceuticals News
- 12.2 Balkan Pharmaceuticals
 - 12.2.1 Company Details
 - 12.2.2 Performance Enhancing Drugs Product Offered
 - 12.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.2.4 Main Business Overview

- 12.2.5 Balkan Pharmaceuticals News
- 12.3 Bayer
 - 12.3.1 Company Details
 - 12.3.2 Performance Enhancing Drugs Product Offered
 - 12.3.3 Bayer Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.3.4 Main Business Overview
 - 12.3.5 Bayer News
- 12.4 AstraZeneca
 - 12.4.1 Company Details
 - 12.4.2 Performance Enhancing Drugs Product Offered
 - 12.4.3 AstraZeneca Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.4.4 Main Business Overview
 - 12.4.5 AstraZeneca News
- 12.5 Novo Nordisk
 - 12.5.1 Company Details
 - 12.5.2 Performance Enhancing Drugs Product Offered
 - 12.5.3 Novo Nordisk Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.5.4 Main Business Overview
 - 12.5.5 Novo Nordisk News
- 12.6 BrainAlert
 - 12.6.1 Company Details
 - 12.6.2 Performance Enhancing Drugs Product Offered
 - 12.6.3 BrainAlert Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.6.4 Main Business Overview
 - 12.6.5 BrainAlert News
- 12.7 Douglas Laboratories
 - 12.7.1 Company Details
 - 12.7.2 Performance Enhancing Drugs Product Offered
 - 12.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.7.4 Main Business Overview
 - 12.7.5 Douglas Laboratories News
- 12.8 Onnit Labs
 - 12.8.1 Company Details
 - 12.8.2 Performance Enhancing Drugs Product Offered

12.8.3 Onnit Labs Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

12.8.4 Main Business Overview

12.8.5 Onnit Labs News

12.9 Eli Lilly And Company

12.9.1 Company Details

12.9.2 Performance Enhancing Drugs Product Offered

12.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

12.9.4 Main Business Overview

12.9.5 Eli Lilly And Company News

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Performance Enhancing Drugs

Table Product Specifications of Performance Enhancing Drugs

Figure Performance Enhancing Drugs Report Years Considered

Figure Market Research Methodo

I would like to order

Product name: 2018-2023 Global Performance Enhancing Drugs Consumption Market Report

Product link: <https://marketpublishers.com/r/2827CF1EC84EN.html>

Price: US\$ 4,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2827CF1EC84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970